New drug shows promise in leukemia battle
NCT ID NCT03258931
First seen Apr 10, 2026 · Last updated Apr 26, 2026 · Updated 2 times
Summary
This study tested a new drug, crenolanib, against an existing drug, midostaurin, in adults aged 18-60 with a specific genetic type of acute myeloid leukemia (FLT3-mutated AML). Participants received one of the two drugs alongside standard chemotherapy and, if eligible, a bone marrow transplant. The goal was to see which drug better prevents the cancer from returning and improves survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NEWLY DIAGNOSED FLT3 MUTATED AML are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deacnss Medical Center Oncology
Boston, Massachusetts, 02215, United States
-
City of Hope National Medical Center
Duarte, California, 91010, United States
-
Columbia University
New York, New York, 10032, United States
-
Cornell University
New York, New York, 10065, United States
-
Dana-Farber Cancer Insitute
Boston, Massachusetts, 02215, United States
-
Henry Ford Health System
Detroit, Michigan, 48202, United States
-
Indiana University
Indianapolis, Indiana, 46206-5149, United States
-
John Theurer Cancer Center at Hackensack UMC
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Memorial Sloan-Kettering Cancer Center
New York, New York, 10065, United States
-
Moffitt Cancer Center
Tampa, Florida, 33612, United States
-
Montefiore Medical Center
The Bronx, New York, 10467, United States
-
Mount Sinai
New York, New York, 10029-6574, United States
-
New York University
New York, New York, 10016, United States
-
Oregon Health and Science University
Portland, Oregon, 97239, United States
-
Ronald Reagan UCLA Medical Center
Los Angeles, California, 90095, United States
-
Roswell Park
Buffalo, New York, 14263, United States
-
Rush Medical Center
Chicago, Illinois, 60612, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
-
The UNC Lineberger Comprehensive Cancer Center
Chapel Hill, North Carolina, 27514, United States
-
US Davis Health
Sacramento, California, 95817, United States
-
University of Chicago
Chicago, Illinois, 60637, United States
-
University of Illinois at Chicago
Chicago, Illinois, 60612, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Kansas
Kansas City, Kansas, 66160, United States
-
University of Minnesota
Minneapolis, Minnesota, 55455, United States
-
University of Rochester Medical Center
New York, New York, 14642, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
-
Wake Forest Baptist Health, Section on Hematology & Oncology
Winston-Salem, North Carolina, 27157, United States
-
Yale Cancer Center
New Haven, Connecticut, 06510, United States
Conditions
Explore the condition pages connected to this study.